BoWangMD

176 posts

BoWangMD

BoWangMD

@BoWangMD1

Bo Wang MD. Executive Member, Lung Cancer Research at Sarah Cannon Research Institute. Hematology-Oncology Willamette Valley Cancer Institute. Views are my own.

Katılım Mart 2019
113 Takip Edilen156 Takipçiler
Sabitlenmiş Tweet
BoWangMD
BoWangMD@BoWangMD1·
My biggest takeaways for #WCLC25 plenary: 1) Flaura2 confirmed as a go to regimen for most classical EGFRmut NSCLC 2) Ivonesvimab + chemo shows benefit over chemotherapy alone in a western population post TKI (EGFRmut) 3) zidesamtinib for ROS1 promising, needs much more maturity
English
1
0
5
353
BoWangMD retweetledi
Eric K. Singhi, MD
Eric K. Singhi, MD@lungoncdoc·
Clear improvement in outcomes with FLAURA2 regimen for EGFRm NSCLC with a TP53 co-mutation. #ELCC26
Uğur Özkerim@UOzkerim

🔥Does adding chemotherapy to osimertinib matter in EGFRm NSCLC with TP53 co-mutations? 👀 In the TOP study: ▫️ mPFS: 34.0 vs 15.6 months (HR 0.44) ▫️ Interim OS: 48.4 vs 36.5 months (HR 0.57) Osimertinib + chemo shows a clear advantage over monotherapy @OncoAlert @MedwatchKate @Larvol @OncoReporte

English
2
7
20
2K
BoWangMD
BoWangMD@BoWangMD1·
@BalazsHalmosMD Except that’s the celebration you get for placing 17th for most of us. 😆
English
0
0
0
29
Balazs Halmos
Balazs Halmos@BalazsHalmosMD·
Young PI completing his/her first IIT P=0.049
Balazs Halmos tweet media
English
2
0
31
1.5K
BoWangMD
BoWangMD@BoWangMD1·
Time will tell - the world is anxious to see Harmoni-3 data for global populations.
Diego A. Díaz-García@diegoadiazg

🫁 Ivonescimab + chemo vs tislelizumab + chemo in stage IIIB–IV sqNSCLC. #HARMONi-6 @myESMO Ivonescimab significantly improved PFS: 11.1 vs 6.9 mo (HR 0.60, p<0.0001), showing consistent benefit across PD-L1 subgroups with manageable safety. Could this dual-target antibody reshape global first-line standards beyond China? #ESMO25 #CánCare #NSCLC #lcsm

English
0
0
0
37
BoWangMD retweetledi
Jarushka Naidoo
Jarushka Naidoo@DrJNaidoo·
Ph III PACIFIC2 trial of concurrent chemoRT + durvalumab v pbo in unresectable stage III NSCLC ⁦@JCO_ASCO⁩: - 328pts - no diff in PFS (HR 0.85, p=0.247), OS (HR 1.03, p=0.823), ORR, or tox Negative study, but important data ⁦@OncoAlert⁩ #LCSM ascopubs.org/doi/10.1200/JC…
English
0
5
34
2.5K
BoWangMD
BoWangMD@BoWangMD1·
Learning about lung cancer updates from our colleagues in Phx, AZ
BoWangMD tweet media
English
0
0
1
70
BoWangMD
BoWangMD@BoWangMD1·
For 2nd and 3rd year fellows who are thinking about first jobs - remember to apply to many job types! Do academic job talks, interview at community and hybrid hospital employed positions, and physician owned practices, and pharma companies. Take time & learn what’s out there 😀
English
1
0
0
36
BoWangMD
BoWangMD@BoWangMD1·
I should amend: #2 meant to write North American (basically USA) - is the biology different ? Hard to tell.
English
0
0
0
29
BoWangMD
BoWangMD@BoWangMD1·
My biggest takeaways for #WCLC25 plenary: 1) Flaura2 confirmed as a go to regimen for most classical EGFRmut NSCLC 2) Ivonesvimab + chemo shows benefit over chemotherapy alone in a western population post TKI (EGFRmut) 3) zidesamtinib for ROS1 promising, needs much more maturity
English
1
0
5
353
BoWangMD retweetledi
Giannis Mountzios
Giannis Mountzios@g_mountzios·
#WCLC25 : Professor Ahn presenting the much awaited results of Ifinatamab DXd ( iDXd) in pretreated pts with #SCLC : ✅ ORR=48.2% in ITT, 56.3% in 2L, 51% in CFTI<90d ✅ mPFS=4.9m, DoR=5.3m, OS=10.3m ✅ mOS=12m for 2L pts! ✅ ILD in 12.4% Ph3 IDeate-Lung02 ongoing! @IASLC @OncBrothers @OncoAlert @VJOncology
Giannis Mountzios tweet mediaGiannis Mountzios tweet mediaGiannis Mountzios tweet mediaGiannis Mountzios tweet media
English
4
17
49
4.5K
BoWangMD
BoWangMD@BoWangMD1·
#WCLC2025 both taletrectinib and zidesamtinib are promising ROS1 targeting agents. TRUST and ARROS programs are both undergoing development. Taletrectenib already FDA approved and pending phase 3 study in China against crizotinib. I will keep my eyes peeled for both
English
0
0
1
156
BoWangMD
BoWangMD@BoWangMD1·
When I don't have a trial for my NSCLC patient but don't want non o dat docetaxel
BoWangMD tweet media
English
0
0
0
42
BoWangMD
BoWangMD@BoWangMD1·
@SarahCannonDocs a great phase 1/2 study for extensive stage small cell lung cancer cancer, on which several of our investigators have placed patients, some of whom are doing really well!! @RachelSanbornMD
Genprex, Inc.@genprex

Dr. Bo Wang presented a poster on the Acclaim-3 clinical trial at #ASCO25 in the Trials in Progress portion of the conference. Visit our website to view the poster that was presented: ow.ly/nBOv50W4pI5 #genetherapy #oncology @bowangmd1

English
0
0
0
10
Shankar Siva
Shankar Siva@_ShankarSiva·
🚨 #ASCO25: Final OS from CheckMate 816 in resectable NSCLC ➡️ NIVO + chemo vs chemo alone (neoadjuvant) ➡️ OS HR 0.66 → 3-yr OS: 80.2% vs 73.4% ➡️ pCR ↑, EFS benefit maintained ⬆️ benefits across subgroups 💥 ?only <50% of control arm received IO at progression? #lcsm
Shankar Siva tweet mediaShankar Siva tweet mediaShankar Siva tweet mediaShankar Siva tweet media
English
2
13
48
3.8K
BoWangMD
BoWangMD@BoWangMD1·
Is anyone going to AACR 2025?
English
0
0
1
55
BoWangMD
BoWangMD@BoWangMD1·
A very interesting study - Benefit/AEs at the 200mg level seem attractive to me. The largest cohort was lung cancer patients, followed by pancreatic - highly relevant! Ponsegromab for the Treatment of Cancer Cachexia | New England Journal of Medicine nejm.org/doi/full/10.10…
English
0
0
1
111

Keşfet

@BalazsHalmosMD @myESMO @OncLive @CParkMD @tugbawitter @Dr_ElvinaA @drmukremin @dr_yakupergun